Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1: early-phase trial registry

6 of 9 indexed B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

9 US clinical trials · 6 currently recruiting · #1,916 of 28,707 conditions by registered trial count

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1: 9 US clinical trials tracked, 6 recruiting.

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.

Enrollment posture brief

Registry condition b-acute-lymphoblastic-leukemia-with-t922q341q112-bcr-abl1

OPEN 6 | RECR 67% | LATE 2 | EARLY 7 | RANK #1916 | SPON 3

Volume-matched condition peers

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

B Acute Lymphoblastic Le (th…67%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 lists 6 open slots (67% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 is recruiting above its size-band peers.

    6 of 9 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 research.

    M.D. Anderson Cancer Center accounts for 3 of 9 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 enrolment sits around 88 participants.

    Median target enrolment is 88 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 25Phase 32

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3 440 participants

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

Children's Oncology Group

NCT05602194
RECRUITING Phase 3 348 participants

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

National Cancer Institute (NCI)

NCT04530565
RECRUITING Phase 1 276 participants

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

NCT01371630
RECRUITING Phase 2 100 participants

Personalized NK Cell Therapy in CBT

M.D. Anderson Cancer Center

NCT02727803
RECRUITING Phase 2 33 participants

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

University of Washington

NCT07224100
RECRUITING Phase 1 20 participants

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

OHSU Knight Cancer Institute

NCT04872790
ACTIVE NOT RECRUITING Phase 2 88 participants

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

NCT01424982
ACTIVE NOT RECRUITING Phase 2 53 participants

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

NCT02143414
COMPLETED Phase 2 16 participants

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

NCT02484430

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 2

Top Sponsors

M.D. Anderson Cancer Center 3 trials
National Cancer Institute (NCI) 3 trials
Children's Oncology Group 1 trials
OHSU Knight Cancer Institute 1 trials
University of Washington 1 trials

Named interventions

Most-linked intervention names on B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cyclophosphamide Drug
5 trials
Blinatumomab Biological
3 trials
Cytarabine Drug
3 trials
Biospecimen Collection Procedure
3 trials
Bone Marrow Aspiration and Biopsy Procedure
2 trials
Dexamethasone Drug
2 trials
Doxorubicin Drug
2 trials
Pharmacological Study Other
1 trials

US sites by state

Facility locations filed on B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 trials. A trial with sites in several states counts in each.

California 4 trials
Texas 3 trials
Arizona 3 trials
Arkansas 3 trials
Alabama 3 trials
Georgia 2 trials
Florida 2 trials
Connecticut 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 page

9 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 6 B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • M.D. Anderson Cancer Center sponsors the most B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 condition card totals 9 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.